Cetuximab resistance is a key barrier in treating metastatic colorectal cancer (mCRC). Targeting of metabolic resources import could resensitize drug-resistant cancer cells to anticancer treatments. Here we showed that the expression of the glutamine transporter solute carrier 1 family member 5 (SLC1A5) in clinical CRC samples of patients resisted to cetuximab was significantly higher than in those of patients responded to cetuximab. Inhibition of SLC1A5 by shRNA-mediated gene silencing or pharmacological inhibitor significantly suppressed the growth of CRC. Moreover, inhibition of SLC1A5 significantly enhanced the inhibitory efficacy of cetuximab on CRC proliferation both in vitro and in vivo. Mechanistically, SLC1A5 inhibition facilitated EGFR degradation through the ubiquitin-proteasome pathway, and decreased the expression of nuclear EGFR, both of which might have contribution to the improved response to cetuximab. This study provides the metabolic molecule SLC1A5 as a potential therapeutic target to increase the efficacy of cetuximab on CRC.
Colorectal cancer (CRC) is the third most common cancer and the fourth leading cause of cancer death globally. 1 CRC patients with loco-regional lesions undergo surgical resection, while those who with metastatic disease would require systemic therapy. For patients with metastatic CRC (mCRC), the typical therapeutic regiments for first-line and secondline are combined employments with fluoropyrimidine (FOL-FIRI/CAPIRI or FOLFOX/CAPOX) and biologic molecular agents targeting the epidermal growth factor receptor (EGFR) (cetuximab or panitumumab) or angiogenesis (bevacizumab, zivaflibercept and ramicurumab). 2, 3 Combined application of cetuximab and conventional chemotherapy reduced the risk of progression of patients with mCRC. 4 However, mCRC patients with RAS-mutation do not benefit from cetuximab treatment, 5 and so far, there is no effective strategy for targeting RAS mutation to reverse cetuximab resistance. Moreover, not all mCRC patients with RAS-wild type (WT) respond to cetuximab treatment, and even some patients with initial response may acquire resistance later after the treatment. 6 Besides the RAS status, other molecular alterations commonly observed following cetuximab treatment-such as amplification or increased level of MET, ERBB2 or ERBB3-could also result in cetuximab resistance. 7, 8 Therefore, it is of clinical significance to investigate potential strategy to improve the CRC response to cetuximab. Deregulating cell metabolism is defined as a hallmark of cancer. 9 Glucose and glutamine are the two basic metabolic resources imported by cancer cells for fueling cellular growth and survival. Blocking of the resource import machinery can effectively increase cancer cell response to antitumor drugs that were previously resisted. 10 Therefore, we wondered whether targeting of the transporters that supplying glucose and glutamine would improve the cancer response to cetuximab. Researches showed that GLUT1, encoding glucose transporter-1, was up-regulated in CRC cells with KRAS or BRAF mutations 11 ; solute carrier 1 family member 5 (SLC1A5), the key transporter of glutamine, was physically associated with EGFR and can be co-targeted by cetuximab in head and neck squamous cell carcinoma. 12 Accordingly, we performed immunohistochemistry to assess the association between the expression of GLUT1/SLC1A5 and the cetuximab efficacy on CRC. It turned out that SLC1A5 but not GLUT1 was highly expressed in tumor tissues of CRC patients with cetuximab resistance, suggesting SLC1A5 may involve in CRC response to cetuximab.
SLC1A5, a member of solute carrier 1, is a sodiumdependent transporter that exchanges neutral amino acid across cell membrane of peripheral tissues. 13 Previous researches showed that SLC1A5 was highly expressed in many types of cancer including CRC and played an important role in promoting tumor growth. [14] [15] [16] [17] [18] [19] So far, supplying glutamine for cellular energy production, macromolecular synthesis, redox homeostasis and mTOR signaling activation is the well-known mechanisms of SLC1A5 for promoting tumor growth. 20 However, the involvement and molecular mechanisms of SLC1A5 in cetuximab treatment on CRC remain largely unknown.
In this study, we aimed to illuminate the role of SLC1A5 in cetuximab treatment on CRC to evaluate SLC1A5 as a potential target for enhancing the efficacy of cetuximab.
Materials and Methods

Patient specimens
Paraffin-embedded samples of stage IV CRC patients with KRAS-WT were collected (n 5 84). These patients were treated with the standard first-line treatments with cetuximab, and did not subject to any other anticancer drug treatments before. Written informed consents were obtained from these patients and paraffin-embedded samples were obtained from Department of Pathology in Nanfang Hospital, Sun Yat-Sen University Cancer Center, and The First Affiliated Hospital of Sun Yat-sen University (from 2012 to 2017). The protocol was approved by the Medical Ethics Committees of Nanfang hospital. Based on the efficacy evaluation of the best clinical response, the patients were classified as responders (complete response, n 5 0; partial response, n 5 25; stable disease, n 5 38) and nonresponders (progressive disease, n 5 21). 21 Compounds, reagents and antibodies Cetuximab (Erbitux TM ) was purchased from Merck (Darmstadt, Germany). GPNA was purchased from MP Biomedicals, CA, USA. MG132, chloroquine, VE821, kU-55933 and NU7441 were purchased from Selleck, Shanghai, China. MTT, BrdU, and glutamine were purchased from SigmaAldrich. Antibodies were as follows: anti-GLUT1 (ABclonal, MA, USA); anti-SLC1A5, anti-gH2AX (Ser-139) (Cell Signaling Technology, MA, USA); anti-GAPDH, anti-pATM, antipATR, anti-pDNAPKcs, anti-EGFR, anti-ubiquitin (Abcam, Cambridge, UK); anti-LC3 (Novus, CO, USA); anti-Histone H3 (GenScript, NJ, USA); anti-Ki67, anti-BrdU, anti-ATP1B1 (Bioworld, MN, USA).
Cell culture and transfection
Cell lines were purchased from Cell Bank of Chinese Academy of Sciences and authenticated using the STR method. Caco2 and SW48 were RAS-WT CRC cell lines. HCT8, HCT116, SW480 and SW620 were RAS-mutant CRC cell lines. Caco2 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) with 20% fetal bovine serum (FBS). SW480, HCT116, SW48 and SW620 cells were maintained in RPMI 1640 with 10% FBS. HCT8 were maintained in DMEM with 10% FBS. All the cells were cultured at 378C under 5% CO 2 . For gene knockdown of SLC1A5, the lentivirus vector GV248 containing specific shRNA (GeneChem, Shanghai, China) was used for stable transduction. Three target sequences used in this study were as follows: SLC1A5-sh1 (CTGAGTTGATACAAGTGAA), SLC1A5-sh2 (AGTCCTTG-GACTTCGTAAA) and SLC1A5-sh3 (TGCTTATCCGCTT-CTTCAA).
Glutamine consumption assays
To detect the ability of L-g-glutamyl-p-nitroanilide (GPNA) to inhibit SLC1A5, cells were cultured with the medium containing different concentrations of GPNA for 48 hr. Then the medium was harvested and the glutamine concentration was detected with the EnzyChrom TM Glutamine Assay Kit (BioAssay Systems, CA, USA) according to the protocol instruction described. The relative amount of glutamine consumption was quantified to the protein content of cells and determined as lmol glutamine/mg protein.
Immunohistochemistry (IHC) staining
IHC staining was performed routinely as previous described. 22 The dilution rates of antibodies were as follows:
1:100 for anti-GLUT1, 1:100 for anti-SLC1A5. The staining was scored as follows: 1 (0-25%), 2 (26-50%), 3 (51-75%) and 4 (76-100%) for proportion of stained area; 0 (negative), 1 (low), 2 (moderate) and 3 (high) for staining intensity. IHC score was calculated by multiplying proportion by intensity. Tissues with scores of 0, 1, 2 and 4 were considered to be low expression and with scores of 6, 8, 9 and 12 were considered to be high expression.
What's new?
Cetuximab is an anti-EGFR drug that is a valuable adjunct therapy for metastatic colorectal cancer (mCRC). Unfortunately, many tumors develop resistance. In this study, the authors found that a glutamine-transporter protein called SLC1A5 is overexpressed in these resistant mCRC cells, and that blocking SLC1A5 activity restores the efficacy of cetuximab. These results support SLC1A5 as a promising therapeutic target for reversing cetuximab resistance.
Western blot
Whole-cell protein, nuclear protein and membrane protein were extracted according to the protocol descriptions of Whole Cell Lysis Assay Kit, Nuclear and Cytoplasmic Protein Extraction Kit and Membrane and Cytoplasmic Protein Extraction Kit (KeyGEN BioTECH, Nanjing, China), respectively. Then, the proteins were fractionated by SDS-PAGE, and finally detected with enhanced chemiluminescence system (Millipore, MA, USA) as previously described. 23 
MTT assay
Cells were seeded in 96-wells plates at a density of 6,000/ wells for 48 hr treatments, and 3,000/wells for 5 days treatments. After the treatment, MTT solution with a final concentration of 0.5 mg/mL was added to each well and incubated at 378C for 4 hr. Then, the crystals were dissolved with 150 lL of dimethyl sulfoxide each well. Finally, the optical density (OD) was detected at 492 nm using Microplate spectrophotometer (SpectraMax M5).
Colony formation assay
Cells were seeded in 6-wells plates at a density of 2,000/well and cultured in the medium containing specific drugs for 2 weeks. Then, the cells were fixed with 4% paraformaldehyde for 15 min and stained with 0.1% crystal violet for 30 min. Thereafter, wells were washed with flush water and the colonies were photographed.
Cell cycle analysis
Caco2 and SW480 cells were treated with PBS or GPNA (10 mM for SW480, 20 mM for Caco2) for 48 hr. At the end of treatment, the cultured cells were harvested, then washed with cold PBS for 3 times and fixed with cold 70% ethanol at 48C overnight. Next, the cells were incubated with 100 lL of RNAase A (KeyGEN BioTECH, Nanjing, China) at 378C water bath for 30 min, and stained with 400 lL of propidiumiodide (KeyGEN BioTECH, Nanjing, China) at 48C for 30 min. After that, cell cycle phase was measured using the flow cytometry system (BD LSRFortessa).
Immunoprecipitation SW480 cells were treated with PBS or 10 mM of GPNA for 48 hr. Before the end of treatment, cells were pre-incubated with 5 lM of MG132 for 24 hr. Then cells were harvested and lysed on ice for 30 min with lysis buffer containing protease inhibitor (Beyotime, Jiangsu, China). The obtained samples were centrifuged at 16,000g for 20 min and the lysate supernatants were collected. Small part of the lysates was taken from every sample and prepared for WB. For immunoprecipitation of ubiquitinated EGFR, the remaining lysates were incubated with EGFR antibody (1:50) at 48C overnight, followed by incubation with protein A-dynabeads (invitrogen TM ) for 4 hr. Next, the beads were washed with lysis buffer for 4 times. Subsequently, the immunoprecipitates were suspended with 1x SDS loading buffer and boiled for 5 min. Finally, the dynabeads were removed and the obtained proteins were fractionated by SDS-PAGE. The ubiquitinated EGFR was detected with ubiquitin antibody.
Immunofluorescence
Caco2 and SW480 cells were treated with PBS, 80 lg/mL of CTX, GPNA (10 mM for SW480, 20 mM for Caco2) or combined treatment for 48 hr, respectively. Then the expression of gH2AX was detected with immunofluorescence assay. Cells were fixed with 4% paraformaldehyde for 15 min and permeabilized with 0.5% Triton X-100 for 12 min. After blocking with 5% bovine serum albumin (BSA) for 30 min at room temperature, the cells were incubated at 48C overnight with gH2AX (Ser-139) antibody (1:800). Next, the cells were incubated with Cy3-labeled secondary antibody (Beyotime, Jiangsu, China) (1:500) at room temperature for 1 hr. Finally, cells were incubated with 5 lg/mL of DAPI (Beyotime, Jiangsu, China) for 5 min and observed under fluorescence microscope (OLYMPUS IX71).
For the experiment detecting the accumulation of singlestrand DNA, Caco2 and SW480 cells were treated with PBS or GPNA (10 mM for SW480 and 20 mM for Caco2), for 48 hr, and the cells were pretreated with 100 lM of BrdU for 2 hr before the end of PBS/GPNA treatment. After these treatments, cells were first subjected to the same treatments as the above (incubating cells with gH2AX antibody and Cy3-labeled secondary antibody). Then, the cells were incubated with BrdU antibody (1:100) at 48C overnight and FITClabeled secondary antibody (Beyotime, Jiangsu, China) (1:500) at room temperature for 1 hr. Thereafter, cells were incubated with 5 lg/mL of DAPI for 5 min. Finally, images were obtained with the fluorescence microscope.
Mouse xenograft model
The animal experiment was approved by the Animal Care and Use Committee of the Nanfang Hospital, Southern Medical University and all animal procedures were performed in accordance with the National Guidelines for Animal Experimentation. BALB/c nude mice (4-to 6-week-old females) were obtained from the Laboratory Animal Center of Southern Medical University. SW480 cells (5 3 10 6 ) were implanted subcutaneously at the right flanks of nude mice and the mice were randomly divided into different treatment groups (5 mice a group). The tumor volume was calculated with the formula: volume 5 length 3 width 2 /2. When the tumor volume reached 200 mm site/hgHeatmap/). The label of the dataset was "TCGA colon & rectum adenocarcinoma (COADREAD) exon expression by RNAseq (IlluminaHiSeq)" and the ID was "TCGA_ COADREAD_exp_HiSeqV2." This dataset contains several files such as "genomicMatix" file and "clinical_data" file. The data of gene expressions and clinical parameters were obtained respectively from the "genomicMatix" file and the "clinical_data" file.
Statistics
Data were reported as means 6 standard deviation (SD). Differences between results were examined using Student's t tests or one-way analysis of variance (ANOVA). Correlations between two categorical variables or continuous variables were examined using v 2 test or Pearson's test, respectively. Survival rates were analyzed with Kaplan-Meier method and examined by log-rank tests. SPSS 22.0 software was used for statistical analysis and a value of p < 0.05 was considered statistically significant.
Results
CRC patients with cetuximab resistance have an overexpression of SLC1A5 in carcinoma tissues
To check the involvement of GLUT1 and SLC1A5 in cetuximab response, we performed IHC to detect their expressions in carcinoma tissues of CRC patients with cetuximab treatment, and analyzed the correlation between their expressions and clinic-pathological features. The GLUT1 expression was associated with patient age (Table 1) , but showed no significant differences in carcinoma tissues between responders and non-responders of both age groups (Figs. 1a and 1b) . No association between SLC1A5 expression and clinicpathological features was detected (Table 1) . However, the SLC1A5 expression in carcinoma tissues was significantly higher in nonresponders than in responders (Fig. 1c) , suggesting that SLC1A5 might be involved in CRC response to cetuximab.
SLC1A5 promotes the proliferation of CRC both in vitro and in vivo
Before assessing the role of SLC1A5 in cetuximab response, we verified the biological function of SLC1A5 in CRC. The SLC1A5 expression in CRC cell lines was examined by WB and it turned out that Caco2 and SW480 cells were SLC1A5-positive (Fig. 2a) . When Caco2 and SW480 cells were treated with GPNA, 24 an activity inhibitor of SLC1A5, the cellular uptakes of glutamine were decreased with the increase of concentrations of GPNA (Fig. 2b) and the cell viabilities were also inhibited (Fig. 2c) . For SLC1A5 knock-down, WB showed that SLC1A5-sh2/3 sequences were effective in Caco2 cells and SLC1A5-sh1/3 sequences were effective in SW480 cells (Fig. 2d) . The cell growth curves demonstrated a slower growth rate in SLC1A5-knockdown cells in contrast to cells with normal SLC1A5 expression (Fig. 2e) . Furthermore, 
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inhibiting SLC1A5 with GPNA caused accumulation of cells in G1 phase and a small reduction of cells in S phase (Fig.  2f) , and increased generation of an autophagy-related protein LC3-II (Fig. 2g) , which was consistent with previous studies reporting that SLC1A5 inhibition-induced cell cycle arrest 17 and autophagy occurrence. 15, 18, 25 In accordance with the in vitro results, inhibiting SLC1A5 with GPNA suppressed tumor growth (Figs. 2h and 2j ) and reduced tumor weight (Fig. 2i ) in mouse xenograft model. Both in vitro and in vivo findings indicated that targeting SLC1A5 suppressed the proliferation of CRC.
Next, we analyzed the SLC1A5 expression in CRC and its correlation to prognosis of CRC patients using the TCGA CRC dataset. Results showed that colorectal tumors overexpressed SLC1A5 in contrast to normal colorectal tissues (Supporting Information, Fig. 1a) . Stage III CRC patients (but not stage I, stage II or stage IV) with higher SLC1A5 expression had a poorer overall survival (OS) (Supporting Information ,  Figs. 1b-1e) . We also evaluated the association between SLC1A5 expression and clinical pathological features of CRC patients using the TCGA CRC dataset. Again, no significant associations between SLC1A5 expression and tumor stage, lymph node, metastasis and other clinical characteristics were observed (Supporting Information, Table 1 ).
Taken together, these results indicated that SLC1A5 played a significant role in CRC proliferation and its overexpression might be related to poor prognosis of stage III CRC patients, although the result was obtained from the TCGA CRC dataset only and further studies are still required.
Inhibition of SLC1A5 enhances the inhibitory efficacy of cetuximab on proliferation of CRC
To further state the significance of SLC1A5 in CRC response to cetuximab, we checked whether inhibition of SLC1A5 Figure 1 . The expressions of GLUT1/SLC1A5 in clinical CRC samples of patients with cetuximab treatment. Representative images of IHC (magnification 1003 for left column, magnification 2003 for middle column and magnification 4003 for right column) and box plot depictions of GLUT1/ SLC1A5 expression in carcinoma tissues of cetuximab responders (R) and cetuximab nonresponders (NR). There was no significant difference in GLUT1 expression between R and NR in both (a) young group (age 50. R, n 5 26; NR, n 5 11) and (b) old group (age > 50. R, n 5 37; NR, n 5 10). (c) The SLC1A5 expression was higher in NR (n 5 21) than in R (n 5 63). Student's t-test. ***p < 0.001 vs R; "ns" means no statistical difference versus R. [Color figure can be viewed at wileyonlinelibrary.com] would improve the CRC response to cetuximab. The MTT test showed that the cell response to cetuximab was effectively improved when with GPNA addition or SLC1A5 knockdown in Caco2 and SW480 cells (Fig. 3a) . SW48, SW620, HCT8 and HCT116 cells were used to further validate this result. As shown in Supporting Information, Figures   2 and 3 , SLC1A5 was positively expressed in these cells and the inhibitory efficacy of cetuximab was also enhanced when inhibiting SLC1A5 with GPNA simultaneously. The colony formation assay presented that cetuximab plus GPNA effectively inhibited the proliferation of CRC cells (Fig. 3b) . Moreover, cetuximab plus GPNA led to more generation of The WB results showed that the generations of (d) gH2AX and (e) LC3-II were significantly increased by combined treatment for 48 h. (f-j) The images of xenograft tumors of 4 groups with different treatments (f). When GPNA was added to cetuximab therapy, the tumor weight was significantly deceased (g); the tumor growth rate was significantly slowed (h); the expression of Ki67 was significantly reduced (i: the representative images were taken at a 4003 magnification; j: the quantitative results were analyzed using Image J software) (Student's t test. **p < 0.01 GCTX vs GPNA, ***p < 0.001 GCTX vs GPNA, "ns" means no statistical difference). "CTX" and "GCTX" is short for "cetuximab" and "GPNA 1 cetuximab," respectively. [Color figure can be viewed at wileyonlinelibrary.com] gH2AX (Figs. 3c and 3d) , a DNA damage marker also been regarded as an indicator of the efficacy of combinatorial therapeutic strategy, 26 and more generation of LC3-II (Fig. 3e) , an important autophagy-related protein. These results suggested that the cell growth was effectively inhibited by cetuximab when SLC1A5 was simultaneously suppressed.
In vivo, we used the nude mouse xenograft model and found that cetuximab monotherapy failed to effectively suppress tumor growth (Figs. 3f-3h) . However, cetuximab combined with GPNA significantly slowed the tumor growth rate (Fig. 3h) and reduced the tumor size and tumor weight (Figs.  3f and 3g) . Consistently, the expression of Ki-67, a proliferation index, was significantly decreased in the tumors with cetuximab plus GPNA treatment (Figs. 3i and 3j) . Overall, these results demonstrated that targeting SLC1A5 with GPNA significantly enhanced the inhibitory efficacy of cetuximab on CRC proliferation.
Targeting SLC1A5 increases the ubiquitin-proteasome pathway mediated EGFR degradation
The ligand-induced EGFR endocytosis would undergo degradation, transport to nucleus or recycle back to membrane. 27, 28 Researches indicated that cell response to EGFR inhibitors could be improved by increasing the degradation of EGFR. 29, 30 Using TCGA CRC dataset, we found that genes that related to EGFR degradation [31] [32] [33] [34] [35] were lower expressed in tumors than in normal tissues ( Supporting Information, Fig.  4 ), and these gene expressions were associated with SLC1A5 expression in different degrees in normal tissues and tumors (Supporting Information, Tables 2 and Supporting Information, 5) . Thus, we speculated that SLC1A5 might involve in EGFR degradation. WB results showed that the EGFR level was significantly decreased by targeting SLC1A5 with GPNA or gene silencing (Fig. 4a) . Moreover, the ubiquitination of EGFR was promoted by GPNA treatment (Fig. 4b) , and the EGFR reduction induced by GPNA could not be compromised by the lysosomal inhibitor chloroquine but was reversed by the proteasome inhibitor MG132 (Fig. 4c) . These results suggested that inhibition of SLC1A5 promoted the degradation of EGFR through the ubiquitin-proteasome pathway, which might contribute to the impact of SLC1A5 in cetuximab response.
Inhibition of SLC1A5 induces DNA damage in CRC cells
As inhibition of SLC1A5 facilitated EGFR degradation, the endocytic EGFR trafficking to cell surface or nucleus would be decreased. 28 This speculation was confirmed by the results that GPNA treatment caused a substantial reduction in the expression of membrane EGFR (mEGFR) and nuclear EGFR (nEGFR) (Fig. 5a ). It has been reported that nEGFR played an important role in DNA replication and DNA damage response and thereby contributes to resistance of multiple therapies. 36 Thus, SLC1A5 might have a function in DNA maintenance as it can regulate the nEGFR expression. By using the TCGA CRC dataset, we found that genes that related to DNA damage response and repair were higher expressed in tumors than in normal tissues ( Supporting  Information, Fig. 6 ), and these gene expressions were associated with SLC1A5 expression in different degrees in normal tissues and tumors (Supporting Information, Table 3 and Supporting Information, 7) . Then, we detected the DNA damage associated markers after genetic or pharmacological inhibition of SLC1A5. WB results revealed that after 48 h incubation with GPNA, the production of gH2AX, a sensitive DNA damage marker, was markedly increased (Fig. 5b) . Likewise, the elevated gH2AX level was observed in SLC1A5-knockdown cells especially in Caco2 with SLC1A5-sh2 sequence and in SW480 with SLC1A5-sh3 sequence (Fig. 5c) . As known, the ataxia telangiectasia mutated (ATM), ataxia telangiectasia and Rad3-related (ATR) and DNA-protein kinase catalytic subunit (DNAPKcs) were the three main kinases that phosphorylated H2AX and triggered distinct DNA damage response. 26 Here, we found that the increased H2AX phosphorylation induced by GPNA was compromised by ATR inhibitor VE821 rather than ATM inhibitor kU-55933 or DNAPKcs inhibitor NU7441 (Fig. 5d) . Consistently, SLC1A5 depletion with shRNA induced elevated phosphorylation of ATR (Fig. 5e) . These results suggested that the DNA damage response induced by inhibition of SLC1A5 was triggered by activated ATR. We also observed that the immunofluorescence staining of bromodeoxyuridine (BrdU) was positive in gH2AX-positive cells after 48 h of GPNA stimulation ( Fig. 5f ), which indicated single-strand DNA (ssDNA) accumulation, a hint at DNA double-strand breaks (DSBs). 37 These results verified that SLC1A5 played an important role in DNA damage response.
Discussion
To date, the persistent activation of the downstream signaling pathways of EGFR is regarded as the main cause of cetuximab resistance. 7 Publications have shown that the amplification or increased level of MET, ERBB2 or ERBB3 contributes to consecutive activation of the downstream signaling of EGFR, leading to tumor resistance to EGFR-targeted treatment, while targeting them resensitizes tumor to cetuximab. 7, 8 However, many drugs that initially present efficacy on these oncogenes or the downstream RAS-MAPK pathway would generally fail because of the emergence of drug resistance. 38 Thus, to concentrate on other factors that potentially affect the cetuximab, sensitivity could be a promising therapeutic strategy for treating mCRC patients.
Many works have implicated functions of metabolic molecules in tumor growth and treatment resistance. 10 In contrast to targeting signal transduction pathways, strategy of targeting key metabolic molecules is less likely to result in drug resistance, because cancer cell is relatively easier to compensate within the signal transduction system than to compensate for a lack of essential metabolic pathway. 10, 38 Here we found that SLC1A5, a key glutamine transporter, was highly expressed in CRC patients with cetuximab resistance. By using multiple CRC cell lines and animal models, we showed that inhibition of SLC1A5 significantly enhanced the inhibitory efficacy of cetuximab on CRC, which supported the concept of targeting cancer metabolic pathway to improve drug response. In general, CRC with RAS-mutation is insensitive to cetuximab. 5 In this work, however, we found that the antitumor effect of cetuximab was improved by simultaneously inhibiting SLC1A5 not only in RAS-WT CRC cell lines (Caco2 and SW48), but also in RAS-mutation CRC cell lines (SW480, SW620, HCT8 and HCT116) and RAS-mutation CRC xenograft model (SW480). This special finding might thus provide SLC1A5 as an important candidate to be targeted for the improved application of cetuximab in CRC regardless of the RAS situation. The involvement of SLC1A5 in cetuximab response led us to study the mechanisms by which SLC1A5 may affect the cetuximab efficacy. Most strikingly, our results revealed that SLC1A5 inhibition enhanced the proteasomal degradation of EGFR. Similarly, Mellinghoff et al. 29 demonstrated that the inactivation of phosphatase and tensin homolog (PTEN) confers resistance to EGFR inhibitor via impairing the degradation of EGFR. Another study by Sukhanova et al. 30 showed that targeting two cholesterol biosynthetic pathway enzymes (sterol C4-methyl oxidase-like, SC4MOL; NADP-dependent steroid dehydrogenase-like, NSDHL) improved sensitivity of cancer cells to EGFR inhibitors including cetuximab by increased EGFR degradation. These two studies presented efficient therapeutic approach of targeting EGFR degradation to enhance the response to EGFR inhibitors. Accordingly, we considered that the effect of increasing EGFR degradation by inhibiting SLC1A5 might contribute to the improved efficacy of cetuximab. Specifically, we and Sukhanova et.al both found that metabolic molecules affect the cetuxiamb response and regulated EGFR degradation. Here, we first showed that the key glutamine transporter SLC1A5 played an important role in regulating EGFR degradation and impairing the cetuximab response. It is worth mentioning that the nuclear transport of EGFR is also regarded as an important barrier to cetuximab therapy. [39] [40] [41] Growing studies indicate that the nEGFR functions as a transcriptional factor in regulating gene expression or as a chromatin regulator in modulating DNA replication and DNA damage response, which leads to cancer resistance to treatments including anti-EGFR targeted therapies, chemotherapy and radiation. Our data showed that SLC1A5 mediated the nEGFR expression, which could be a mechanism for the regulating function of SLC1A5 in DNA maintenance. These newfound functions might also explain the influence of SLC1A5 on cetuximab response.
One of the most important mechanisms of action of cetuximab is competing with endogenous ligands to block the membrane function of EGFR and induce EGFR endocytosis. 27 The fates of endocytic EGFR include (i) degradation; (ii) transporting to nucleus and (iii) recycling back to cell surface. 28 As discussed above, the enhanced cetuximab efficacy induced by SLC1A5 inhibition might be ascribed to the increased EGFR degradation and reduced nEGFR expression. In addition, inhibition of SLC1A5 also decreased the mEGFR expression. Thus, we suspect that the effect of SLC1A5 in cetuximab response might be a result of the intervention of SLC1A5 in the fates of cetuximab-induced endocytic EGFR. For the first time, we put forward that targeting SLC1A5 might affect the fates of the endocytic EGFR and then boost the action of cetuximab, thereby providing a novel strategy for treating mCRC patients.
This work also reveals the new functions of SLC1A5. We found SLC1A5 regulate the degradation and nuclear expression of EGFR, and function in DNA damage response. These findings enrich our understanding of SLC1A5, and provide more experimental evidence for the idea of developing SLC1A5 as an antitumor target.
In summary, this study not only provides insights into understanding the role of SLC1A5 in promoting the malignant behavior of CRC but also supports SLC1A5 as an attractive therapeutic target for improving the CRC response to cetuximab regardless of RAS-WT or RAS-mutation.
